Tvardi Therapeutics (TVRD) Equity Average: 2013-2017
Historic Equity Average for Tvardi Therapeutics (TVRD) over the last 5 years, with Sep 2017 value amounting to $104.1 million.
- Tvardi Therapeutics' Equity Average rose 34.91% to $104.1 million in Q3 2017 from the same period last year, while for Sep 2017 it was $104.1 million, marking a year-over-year increase of 34.91%. This contributed to the annual value of $77.9 million for FY2016, which is 0.60% down from last year.
- Latest data reveals that Tvardi Therapeutics reported Equity Average of $104.1 million as of Q3 2017, which was up 50.40% from $69.2 million recorded in Q2 2017.
- Over the past 5 years, Tvardi Therapeutics' Equity Average peaked at $109.5 million during Q4 2015, and registered a low of -$53.0 million during Q4 2013.
- Moreover, its 3-year median value for Equity Average was $77.2 million (2016), whereas its average is $74.8 million.
- Its Equity Average has fluctuated over the past 5 years, first soared by 830.12% in 2015, then tumbled by 60.00% in 2017.
- Over the past 5 years, Tvardi Therapeutics' Equity Average (Quarterly) stood at -$53.0 million in 2013, then soared by 200.87% to $53.5 million in 2014, then spiked by 104.59% to $109.5 million in 2015, then slumped by 44.03% to $61.3 million in 2016, then surged by 34.91% to $104.1 million in 2017.
- Its last three reported values are $104.1 million in Q3 2017, $69.2 million for Q2 2017, and $40.0 million during Q1 2017.